As a tyrosine kinase inhibitor targeting BCR-ABL, ponatinib has been used to treat chronic myeloid leukemia. Here, the authors identify LCK and PI3K signaling as additional ponatinib targets, with ponatinib inducing CD8+ T stem cell memory cells, thereby boosting immune checkpoint blockade and CAR T cell therapy.
- Yuki Okuhiro
- Sachiko Ito
- Hiroyoshi Nishikawa
